Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 8:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,616 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cohort A: placebo Clear all
Completed Phase 2 Interventional

Dose-escalating Safety Study in Subjects on Stable Statin Therapy

NCT00231569
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
ISIS 301012 or Placebo
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Auburn, Maine
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Oct 15, 2026, 8:57 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of LY4064912 in Healthy Participants and With Overweight or Obesity

NCT07152002
View directory record Official record
Conditions
Overweight or Obesity, Healthy
Interventions
LY4064912, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Los Alamitos, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 15, 2026, 8:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and PK Study of EC-18 in Healthy Subjects

NCT02496143
View directory record Official record
Conditions
Chemotherapy-induced Neutropenia
Interventions
EC-18, Placebo
Drug
Lead sponsor
Enzychem Lifesciences Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Oct 15, 2026, 8:57 AM EDT
Withdrawn Not applicable Interventional

Crossover Blinded Trial of Cell Therapy Versus Placebo in COPD

NCT03228121
View directory record Official record
Conditions
COPD, Emphysema or COPD, Chronic Bronchitis
Interventions
Treatment Then Placebo, Placebo Then Treatment
Procedure
Lead sponsor
Lung Institute
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 15, 2026, 8:57 AM EDT
Completed Phase 1Phase 2 Interventional

Single Ascending Doses Study of KLS-2031 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy

NCT04238793
View directory record Official record
Conditions
Neuropathic Pain From Lumbosacral Radiculopathy
Interventions
KLS-2031, Placebo
Drug · Other
Lead sponsor
Kolon Life Science
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 15, 2026, 8:57 AM EDT
Completed Phase 2 Interventional Results available

AZD9773 Dose Escalation Study

NCT00615017
View directory record Official record
Conditions
Severe Sepsis
Interventions
AZD9773 (CytoFab), Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Newark, Delaware • Bay Pines, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Oct 15, 2026, 8:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

NCT00454818
View directory record Official record
Conditions
Heart Failure, Congestive, Dilated Cardiomyopathy
Interventions
MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study), Placebo Infusion, MYDICAR Phase 2 (Placebo-controlled, Randomized Study)
Genetic · Procedure
Lead sponsor
Celladon Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
22
States / cities
San Diego, California • Gainesville, Florida • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 15, 2026, 8:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Sequential Single and Multiple Ascending Dose (SAD/MAD) Study of SK10 Powders in Healthy Adult Subjects

NCT06026397
View directory record Official record
Conditions
Chemotherapy-induced Diarrhea
Interventions
SK10, Placebo
Drug
Lead sponsor
Guangzhou Zhiyi Biotechnology Co., Ltd.
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 15, 2026, 8:57 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

NCT04752774
View directory record Official record
Conditions
Spasticity
Interventions
Corabotase, Placebo, Dysport
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
5
States / cities
Downey, California • Overland Park, Kansas • Farmington Hills, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 15, 2026, 8:57 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Brain Blood Vessel Responses to Changes in Blood Flow: Younger Cohort

NCT06629090
View directory record Official record
Conditions
Magnetic Resonance Imaging, Cerebrovascular Circulation
Interventions
MRI, Prazosin, Placebo
Device · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
20 Years to 40 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 15, 2026, 8:57 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT05648214
View directory record Official record
Conditions
Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions
ALN-PNP, Placebo (PB)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
6
States / cities
Glendale, California • Los Angeles, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 15, 2026, 8:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity

NCT05369390
View directory record Official record
Conditions
Obesity
Interventions
NNC0487-0111 A, NNC0487-0111 B, Placebo B (NNC0487-0111 B), Placebo A (NNC0487-0111 A)
Drug · Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 15, 2026, 8:57 AM EDT
Not listed Phase 1Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure

NCT01961726
View directory record Official record
Conditions
Ischemic Heart Failure
Interventions
Placebo, 30 mg dose of JVS-100, 45 mg dose of JVS-100
Biological
Lead sponsor
Juventas Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Birmingham, Alabama • Gainsville, Florida • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Oct 15, 2026, 8:57 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes® in Healthy Human Subjects; A Microdose Escalation Study (Cohorts 1 - 4) and Repeat Microdose Immunogenicity Study (Cohort 5)

NCT02223117
View directory record Official record
Conditions
Healthy
Interventions
Thrombosomes, Placebo
Biological
Lead sponsor
Cellphire Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 15, 2026, 8:57 AM EDT
Terminated Phase 1 Interventional

BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES

NCT03658135
View directory record Official record
Conditions
Primary Tauopathies, Corticobasal Degeneration Syndrome, Frontotemporal Lobar Degeneration With Tau Inclusions, MAPT Mutation Carriers, Symptomatic, Traumatic Encephalopathy Syndrome, Nonfluent Aphasia, Progressive
Interventions
BIIB092, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
35 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Oct 15, 2026, 8:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's Patients

NCT04350177
View directory record Official record
Conditions
Healthy Elderly, Parkinson Disease
Interventions
IkT-148009, Placebo
Drug
Lead sponsor
ABLi Therapeutics, Inc.
Industry
Eligibility
55 Years to 70 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Long Beach, California • Hallandale, Florida • Farmington Hills, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 15, 2026, 8:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants

NCT05654181
View directory record Official record
Conditions
Healthy
Interventions
PF-07328948, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 15, 2026, 8:57 AM EDT
Terminated Phase 2 Interventional

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis

NCT01261403
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
PDA001, Vehicle Controlled Placebo
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
16
States / cities
Anniston, Alabama • Arcadia, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 15, 2026, 8:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Staccato® Granisetron Multiple Dose PK

NCT04327765
View directory record Official record
Conditions
Healthy
Interventions
0.5mg AZ-010, 1mg AZ-010, 3mg AZ-010
Combination Product
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 15, 2026, 8:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study LY2228820 for Recurrent Ovarian Cancer

NCT01663857
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
LY2228820, Carboplatin, Placebo, Gemcitabine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Sarasota, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 15, 2026, 8:57 AM EDT
Completed Phase 2 Interventional

A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

NCT06693843
View directory record Official record
Conditions
Obesity, Overweight, or Chronic Weight Management
Interventions
Aleniglipron or Placebo, Aleniglipron
Drug
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
39
States / cities
Phoenix, Arizona • Anaheim, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 15, 2026, 8:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Dosing Administration of MF-300 in Healthy Participants

NCT07613684
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MF-300 SAD, Placebo, MF-300 Food Effect, MF-300 MAD
Drug
Lead sponsor
Epirium Bio Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Marlton, New Jersey • Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 15, 2026, 8:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese Participants

NCT05813717
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986325, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 15, 2026, 8:57 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis

NCT07558668
View directory record Official record
Conditions
Moderate to Severe Atopic Dermatitis
Interventions
SYX-5219 Oral Capsule
Drug
Lead sponsor
Sitryx Therapeutics Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
6
States / cities
Arkansas City, Arkansas • Fremont, California • Plainfield, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 15, 2026, 8:57 AM EDT